All news

Piper Sandler starts Innoviva at Overweight with $29 target

Alpha Vantage · TradingView · · AI-summarised by FinFlash

Innoviva shares rose after Piper Sandler initiated coverage with an Overweight rating and a $29 price target, citing the company's diversified biopharma exposure. Analyst David Amsellem highlighted Innoviva's royalty portfolio and hospital-focused brand assets, which let investors benefit from FDA-approved treatments without typical development-stage risks. The company also holds strategic investments in development-stage biopharma firms.

Read original source

INVA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.